Journal article
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
Abstract
BACKGROUND: Exemestane can prevent breast cancer in postmenopausal women. Because of potential widespread use, we examined the safety of exemestane on bone health.
METHODS: In this nested safety substudy of the MAP.3 trial (a randomised, placebo-controlled, double-blind trial of exemestane 25 mg a day for the primary prevention of breast cancer), we included postmenopausal women from five centres who were eligible to participate in MAP.3, not …
Authors
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M
Journal
The Lancet Oncology, Vol. 13, No. 3, pp. 275–284
Publisher
Elsevier
Publication Date
March 2012
DOI
10.1016/s1470-2045(11)70389-8
ISSN
1470-2045
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Absorptiometry, PhotonAndrostadienesAnticarcinogenic AgentsAromatase InhibitorsBone DensityBone and BonesBreast NeoplasmsCalciumCanadaChi-Square DistributionDietary SupplementsDouble-Blind MethodFemaleFemur NeckHip JointHumansLumbar VertebraeMiddle AgedOsteoporosisPatient SelectionPlacebosPostmenopausePrimary PreventionRisk AssessmentRisk FactorsTime FactorsTomography, X-Ray ComputedTreatment OutcomeUnited StatesVitamin D